NodThera

Executive Summary

NodThera, a UK-based biotechnology company founded in 2016, is advancing a pipeline of small molecule NLRP3 inflammasome inhibitors for the treatment of chronic inflammatory diseases. The NLRP3 inflammasome is a key driver of inflammation implicated in a range of disorders, including neurodegenerative diseases, cardiovascular conditions, and metabolic syndromes. NodThera's lead candidate, NT-0796, is a brain-penetrant, potent inhibitor undergoing clinical evaluation for Parkinson's disease and other CNS indications. The company has reported promising preclinical data demonstrating target engagement and disease modification, and early clinical results have shown favorable safety and pharmacokinetics. With a strong scientific foundation and a clear focus on a validated but underdeveloped target, NodThera is well-positioned to address high unmet medical needs. The company's private status and lack of disclosed funding suggest it may seek additional capital or a partnership to support later-stage trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data for NT-0796 in Parkinson's disease40% success
• Q1 2027Initiation of Phase 2 trial of NT-0796 in Alzheimer's disease50% success
• Q2 2027Partnership or licensing deal for NT-0796 or pipeline30% success